The sales leader who spent 18 years teaching Fortune 500s to buy automation, then quit to sell it to hospitals himself.
He is wearing the mid-blue shirt of a person who has been in enough boardrooms to know the light is bad and the coffee is worse. Behind him, nothing - which is the point.
Reveal HealthTech occupies a strange corner of the AI story. It doesn't diagnose cancer, it doesn't discover drugs, and it doesn't build a chatbot for your doctor. It builds AI agents that do the parts of medicine nobody makes movies about - clinical trial recruitment, patient adherence, workflow automation - and the pitch is that this is where the money is.
Sanchit Mullick, the CEO, put the case plainly in an interview: "AI in healthcare is often equated with clinical decision support. But that's just a sliver of the opportunity. We are using AI to amplify and streamline clinical workflows." The sliver is the shiny part. The rest is where hospitals actually spend money.
Reveal was founded in January 2023 with two co-founders: Dr. Salim Afshar, a surgeon who now sits as Chief Medical & Innovation Officer, and Andrew Bravo, the operator. Sanchit brought the go-to-market. The three of them incubated the company inside W Health Ventures and 2070 Health, which is an unusual origin - most healthtech founders raise pre-seed on a warm intro; Reveal essentially rented an accelerator, twice.
The product surface is two things. BioCanvas® is a multimodal AI platform aimed at speeding up clinical trial recruitment, which is the kind of problem that costs pharma companies roughly a year and a hundred million dollars every time it happens. Prism AI® is the workflow-agent side of the house - the tool you point at a hospital's billing or intake operation when the humans doing it have been there too long to be cheap and not long enough to be fast.
The company's biggest reference story, cited in the Series A press release, is a $40 billion medical device manufacturer whose patient-adherence problem Reveal solved with AI-driven data integration. The claim is that the implementation is replicable, which is a claim every services firm makes and only some can prove.
On September 3, 2025, Leo Capital led a $7.2 million Series A with participation from Sanos Capital. The company has now raised roughly $16 million across three rounds, or, if you prefer the pitch-deck arithmetic, $27.3 million in total funding depending on which data source you consult - the difference being the incubator equity, which some databases count and others don't.
Reveal's team is roughly 85 people across New York and India. The New York address is 500 7th Avenue, midtown Manhattan, close enough to the pharma corridor to get to meetings, far enough from Wall Street to be forgotten by it.
Sanchit joined Infosys in April 2003 as a senior consultant in CRM, which in 2003 was the closest thing enterprise software had to a hot category. He would not leave the company for eighteen years. He was in the U.S., then Australia, then the U.K., then India, then the U.S. again, in a rotation that reads like a passport stamp collection organized by fiscal quarter.
By 2017 he was Global Head of Sales for AI & Automation and Digital Workplace Services - a title with the classic Infosys quality of sounding like three business lines glued together, because it was. He was on the founding team of that practice. Building it meant selling something called RPA to companies who did not yet know what RPA was.
In a 2020 interview with Unite.AI, he described the thesis in the plain language of a person who has given the same pitch four hundred times: "From the very beginning we have housed automation and AI capabilities under a single umbrella, and by doing so we bring various technology interventions together to solve a business problem in the best way possible." Translation: the customer doesn't care which technology you use.
In March 2021 he left Infosys for GlobalLogic, where he ran Private Equity sales for twenty-one months. Then, in January 2023, he stopped selling other people's automation and started his own.
If you spend twenty years selling automation and you look at healthcare in 2023, this is the sentence you say. The EHR era was the pipe-laying. The AI era is what runs through it.
Reveal is a services company with two productized offerings, which is the honest way to say it. Both have registered trademarks, which is the tell.
A multimodal AI platform aimed at pharma. The lead use case is clinical trial recruitment - matching patients to trials fast enough to matter to a trial timeline. The audience is Fortune 100 pharma and mid-sized biotech; the pain is a problem the industry has been trying to solve since long before large language models existed.
An intelligent-agent development platform for workflow automation. Reveal points it at hospital operations - the intake, billing, staffing, adherence work that keeps a health system running and quietly burns half its revenue. Prism is what you get when a career RPA seller decides the RPA era is over.
Our mission is simple but bold. We want to make AI the most trusted and accountable partner in healthcare, driving breakthroughs for everyone from Fortune 100 pharma companies and large healthcare delivery systems to emerging innovators in digital health.
Series A announcement · Sept 2025AI in healthcare is often equated with clinical decision support. But that's just a sliver of the opportunity. We are using AI to amplify and streamline clinical workflows.
Podcast · Navigating AI in HealthcareThe country had just seen about 20 years of electronic health record implementations, and there was this gold mine of digital data that could be leveraged.
Founding thesis, on healthcare dataIn all of this, it is important to remain focused on solving real world problems.
Unite.AI interview, Infosys eraThe founding trio is unusual. Most healthtech companies are founded by two clinicians, or two engineers, or a clinician and an engineer. Reveal is a surgeon, an operator and a sales leader. That composition tends to produce companies that sell before they build, which is either a strength or a warning depending on which side of the term sheet you're on.
The dual incubation is unusual too. W Health Ventures and 2070 Health both incubated Reveal before Series A. Most companies pick one. Doing both suggests the founders wanted operating cover more than dilution efficiency, which is a rational thing to want if you have never founded a company before and your business is healthcare.
The products carry registered trademarks. BioCanvas® and Prism AI® both display the ® mark, which requires actual USPTO registration rather than a vibes-based ™. Filing before Series A is a small legal expense that signals a founder team thinking about defensibility earlier than most.
The company's reference customer is huge. The Series A press cites a $40 billion medical device manufacturer as a Reveal engagement. A company Reveal's size normally lists three logos and blurs two of them. This is a two-year-old firm claiming a case study bigger than most competitors' entire book.
The passport. Sanchit has done tours in the U.S., U.K., Australia and India across his Infosys years. The company's actual footprint - New York plus India - mirrors that. Founders tend to build the geography they know how to manage.
The pitch language. He uses the words "trusted" and "accountable" together in his standard mission statement. Those are compliance words, not marketing words. If you sell AI to hospitals, you are selling to procurement and legal before you are selling to a doctor. He knows that.